Curis Q3 net loss $12.2M ($2.13/sh); cash $68.5M; emavusertib studies resume

CURIS INC

2023-Q3 EPS reported -$6.96 revenue$7,327,000

Net loss narrowed to $12.2M from $13.3M YoY; revenue unchanged at $2.8M from Erivedge royalties.
Cash, cash equivalents and investments total $68.5M; company expects funding into 2025.
Patient enrollment restarted in Phase 1/2 TakeAim Leukemia and Lymphoma emavusertib studies after partial clinical hold lift.
Plans to initiate triplet combo study of emavusertib with azacitidine and venetoclax in AML in Q4 2023.
Updated TakeAim Lymphoma data expected at ASH December 2023; leukemia data in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CURIS INC reported third quarter of 2023 results: revenue $2.8 million, net income $12.2 million, EPS $2.13.

Period: third quarter of 2023
Revenue: $2.8 million
Net income: $12.2 million
EPS: $2.13
Result: reported results

Exact text from the filing

to a net loss of $45.3 million or $9.82 per share on both a basic and diluted basis for the same period in 2022. Revenues for the third quarters of 2023 and 2022 were both $2.8 million. Revenues for both periods consist of royalty revenues from Genentech and Roche's sales of Erivedge®. Revenues for the nine months ended September 30, 2023 and 2022 were both

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-23-000073

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.